DE69941214D1 - DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE - Google Patents
DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENEInfo
- Publication number
- DE69941214D1 DE69941214D1 DE69941214T DE69941214T DE69941214D1 DE 69941214 D1 DE69941214 D1 DE 69941214D1 DE 69941214 T DE69941214 T DE 69941214T DE 69941214 T DE69941214 T DE 69941214T DE 69941214 D1 DE69941214 D1 DE 69941214D1
- Authority
- DE
- Germany
- Prior art keywords
- panca
- microbial
- ulcerative colitis
- methods
- antigene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/041,889 US6033864A (en) | 1996-04-12 | 1998-03-12 | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
PCT/US1999/005492 WO1999045955A1 (en) | 1998-03-12 | 1999-03-12 | DIAGNOSIS, PREVENTION AND TREATMENT OF ULCERATIVE COLITIS, AND CLINICAL SUBTYPES THEREOF, USING MICROBIAL UC pANCA ANTIGENS |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69941214D1 true DE69941214D1 (de) | 2009-09-17 |
Family
ID=21918893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69941214T Expired - Lifetime DE69941214D1 (de) | 1998-03-12 | 1999-03-12 | DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE |
Country Status (8)
Country | Link |
---|---|
US (3) | US6033864A (de) |
EP (1) | EP1069907B1 (de) |
AT (1) | ATE438407T1 (de) |
AU (1) | AU3002699A (de) |
CA (1) | CA2322763C (de) |
DE (1) | DE69941214D1 (de) |
HK (1) | HK1035662A1 (de) |
WO (1) | WO1999045955A1 (de) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9924351D0 (en) | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
US6348316B1 (en) * | 2000-04-12 | 2002-02-19 | Cedars-Sinai Medical Center | Genetic testing for determining the risk of pouchitis development |
US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
US6821739B2 (en) * | 2000-10-13 | 2004-11-23 | The Regents Of The University Of California | Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens |
GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
US20040029786A1 (en) * | 2002-05-08 | 2004-02-12 | Das Kiron M | Treatment of ulcerative colitis by introducing CEP antigen composition |
US20080193945A1 (en) * | 2002-06-25 | 2008-08-14 | Index Diagnostics Ab | Method and Kit for the Diagnosis of Ulcerative Colitis |
AU2003268473B2 (en) * | 2002-09-05 | 2009-11-19 | Techlab, Inc. | Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anti-neutrophil cytoplasmic antibodies (ANCA) |
DE60321027D1 (de) * | 2002-10-25 | 2008-06-26 | Techlab Inc | Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon |
CN101302556B (zh) * | 2002-12-18 | 2011-05-25 | 生物技术部 | 编码结核分枝杆菌组蛋白样蛋白质的hupB基因的鉴定 |
US20050058663A1 (en) * | 2003-09-17 | 2005-03-17 | Monif Gilles R. G. | Mycobacterium avium subspecies paratuberculosis oral vaccine and methods |
US7592150B2 (en) * | 2003-12-03 | 2009-09-22 | Glycominds, Ltd | Method for diagnosing diseases based on levels of anti-glycan antibodies |
US20060205022A1 (en) * | 2003-12-03 | 2006-09-14 | Nir Dotan | Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease |
CA2546837A1 (en) * | 2003-12-03 | 2005-06-16 | Glycominds Ltd. | Method for diagnosing diseases based on levels of anti-glycan antibodies |
US20060154276A1 (en) | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
US7759079B2 (en) * | 2004-05-13 | 2010-07-20 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
EP1820855A4 (de) * | 2004-09-03 | 2010-05-12 | Amateraspharma Inc | Monoklonaler anti-histon-h1-antikörper sowie zu dessen herstellung fähiges hybridom |
EP2280085A3 (de) * | 2004-11-01 | 2011-02-23 | George Mason University | Zusammensetzungen und Verfahren zur Diagnose von Kolonerkrankungen |
US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
US8685741B1 (en) | 2007-03-07 | 2014-04-01 | Nestec S.A. | Methods for diagnosing irritable bowel syndrome |
AU2008279584A1 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
US20110136255A1 (en) * | 2007-11-30 | 2011-06-09 | Nir Dotan | Composition and method for prediction of complicated disease course in crohn's disease |
WO2009082298A1 (en) * | 2007-12-20 | 2009-07-02 | Index Diagnostics Ab | Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd |
AU2009314259B2 (en) * | 2008-11-11 | 2015-06-11 | Nestec S.A. | Methods for prediction of inflammatory bowel disease (IBD) using serologic markers |
EP2419529B1 (de) | 2009-04-14 | 2015-05-20 | Nestec S.A. | Prognostik entzündlicher darmerkrankung |
EP2445517B1 (de) | 2009-06-25 | 2014-07-30 | Nestec S.A. | Verfahren zur diagnostizierung des reizdarmsyndroms |
WO2011060098A1 (en) | 2009-11-10 | 2011-05-19 | Prometheus Laboratories Inc. | Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis |
US8445215B1 (en) | 2010-07-23 | 2013-05-21 | Nestec S.A. | Assays and methods for the detection of Crohn's disease |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
RU2013142278A (ru) | 2011-02-17 | 2015-03-27 | Нестек С.А. | ТЕСТЫ ДЛЯ ДЕТЕКЦИИ АУТОАНТИТЕЛ К АНТИ-TNFα ЛЕКАРСТВЕННЫМ СРЕДСТВАМ |
EP2707504A1 (de) | 2011-05-10 | 2014-03-19 | Nestec S.A. | Verfahren zur profilerstellung einer krankheitsaktivität für personalisiertes therapiemanagement |
EP2710383B1 (de) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Leistungsfähigkeit eines Biomarkerpanels für Reizdarmsyndrom |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
US10988516B2 (en) * | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
US9128098B2 (en) | 2012-10-31 | 2015-09-08 | Gilles R. G. Monif | Fuidi herd management and risk stratification methods |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
MX2016005822A (es) | 2013-11-04 | 2016-12-02 | Uti Limited Partnership | Metodos y composiciones para inmunoterpia sostenida. |
CA2932571A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Methods for predicting post-operative recurrence of crohn's disease |
US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
AU2015335907A1 (en) | 2014-10-21 | 2017-04-13 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
SG10202105996WA (en) | 2014-12-23 | 2021-07-29 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
KR20220151045A (ko) | 2014-12-23 | 2022-11-11 | 4디 파마 리서치 리미티드 | 면역 조정 |
US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MD3240554T2 (ro) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune |
PL3206700T3 (pl) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Kompozycje zawierające szczepy bakteryjne |
AU2016349703A1 (en) | 2015-11-06 | 2018-11-01 | Vetica Labs, Inc. | Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals |
ME03003B (de) | 2015-11-20 | 2018-10-20 | 4D Pharma Res Ltd | Zusammensetzungen mit bakterienstämmen |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
RS58869B1 (sr) | 2016-03-04 | 2019-08-30 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za lečenje visceralne hipersenzitivnosti |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
TWI787272B (zh) | 2017-05-22 | 2022-12-21 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
JP6978514B2 (ja) | 2017-05-24 | 2021-12-08 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
KR20200015575A (ko) | 2017-06-14 | 2020-02-12 | 4디 파마 리서치 리미티드 | 세균 균주를 포함하는 조성물 |
JP6884889B2 (ja) | 2017-06-14 | 2021-06-09 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
WO2019186084A1 (en) * | 2018-03-26 | 2019-10-03 | The University Of Liverpool | Anti-complement histones |
US20210254122A1 (en) * | 2018-03-29 | 2021-08-19 | Kimberly-Clark Worldwide, Inc. | Sensor for indicating a potential forthcoming skin or gastrointestinal issue and methods of using the same |
CN111187344A (zh) * | 2019-12-19 | 2020-05-22 | 北京安锐鑫生物科技有限公司 | 多肽、包含其的组合物、及其预防或治疗皮肤损伤或抗氧化药物的应用 |
WO2023076924A1 (en) * | 2021-10-26 | 2023-05-04 | Rensselaer Polytechnic Institute | Systems and methods for increased production of recombinant biopolymers via genome engineering and downregulation of basal expression |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003003A1 (en) * | 1984-01-12 | 1985-07-18 | Volker Rusch | Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes |
US5830675A (en) * | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
US6074835A (en) * | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
AU2992497A (en) * | 1996-04-12 | 1997-11-07 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone h1 |
-
1998
- 1998-03-12 US US09/041,889 patent/US6033864A/en not_active Expired - Lifetime
-
1999
- 1999-03-12 CA CA2322763A patent/CA2322763C/en not_active Expired - Lifetime
- 1999-03-12 WO PCT/US1999/005492 patent/WO1999045955A1/en active Application Filing
- 1999-03-12 AU AU30026/99A patent/AU3002699A/en not_active Abandoned
- 1999-03-12 DE DE69941214T patent/DE69941214D1/de not_active Expired - Lifetime
- 1999-03-12 AT AT99911375T patent/ATE438407T1/de not_active IP Right Cessation
- 1999-03-12 EP EP99911375A patent/EP1069907B1/de not_active Expired - Lifetime
- 1999-10-12 US US09/417,264 patent/US6537768B1/en not_active Expired - Lifetime
-
2001
- 2001-07-16 HK HK01104951.8A patent/HK1035662A1/xx unknown
-
2002
- 2002-08-27 US US10/229,567 patent/US7183065B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1999045955A9 (en) | 2000-02-17 |
EP1069907A4 (de) | 2003-03-05 |
WO1999045955A1 (en) | 1999-09-16 |
US7183065B2 (en) | 2007-02-27 |
CA2322763A1 (en) | 1999-09-16 |
US20030092080A1 (en) | 2003-05-15 |
HK1035662A1 (en) | 2001-12-07 |
CA2322763C (en) | 2012-05-01 |
EP1069907A1 (de) | 2001-01-24 |
EP1069907B1 (de) | 2009-08-05 |
ATE438407T1 (de) | 2009-08-15 |
AU3002699A (en) | 1999-09-27 |
US6033864A (en) | 2000-03-07 |
US6537768B1 (en) | 2003-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69941214D1 (de) | DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE | |
CY1109437T1 (el) | ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ | |
ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
DE60331941D1 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
ATE418565T1 (de) | Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden | |
DE69322860T2 (de) | Antikörper gegen alpha v beta 3 integrin | |
ATE268385T1 (de) | Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose | |
DE69526973T2 (de) | Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel | |
ATE244018T1 (de) | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer | |
TR199900656T2 (xx) | �ndanonlar ile 262 ve 20S proteazomun engellenmesi. | |
RU94046284A (ru) | Способ обнаружения антител, способ с-крекинга компонентов крови, набор для обнаружения антител к hcv | |
HUP0101719A2 (hu) | Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával | |
BR0113213A (pt) | Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo | |
PL309637A1 (en) | Diagnostic test and therapy for demyelination diseases such as multiple sclerosis | |
DE69638024D1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
SE8701905D0 (sv) | A method and a kit for the diagnosis of iga nephropathy | |
EA200100264A1 (ru) | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly | |
NO994750L (no) | Anti-Fas-antistoffer | |
DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
DE3854267T2 (de) | HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung. | |
WO2003081206A3 (en) | Stratification of patient populations having or suspected of having rheumatoid arthritis | |
DE69129582T2 (de) | Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay | |
EP0563244A4 (en) | Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis | |
DE59209888D1 (de) | Monoklonale antikörper gegen das humane tnf-bindende protein i (tnf-bp i) | |
SE9904236D0 (sv) | Immunoassay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |